574 related articles for article (PubMed ID: 27263022)
1. Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review.
Rauhavirta T; Hietikko M; Salmi T; Lindfors K
Clin Rev Allergy Immunol; 2019 Aug; 57(1):23-38. PubMed ID: 27263022
[TBL] [Abstract][Full Text] [Related]
2. Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.
Martucciello S; Paolella G; Esposito C; Lepretti M; Caputo I
Cell Mol Life Sci; 2018 Nov; 75(22):4107-4124. PubMed ID: 30136165
[TBL] [Abstract][Full Text] [Related]
3. Transglutaminase 2-targeted autoantibodies in celiac disease: Pathogenetic players in addition to diagnostic tools?
Lindfors K; Mäki M; Kaukinen K
Autoimmun Rev; 2010 Sep; 9(11):744-9. PubMed ID: 20547248
[TBL] [Abstract][Full Text] [Related]
4. Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process.
Fleckenstein B; Molberg Ø; Qiao SW; Schmid DG; von der Mülbe F; Elgstøen K; Jung G; Sollid LM
J Biol Chem; 2002 Sep; 277(37):34109-16. PubMed ID: 12093810
[TBL] [Abstract][Full Text] [Related]
5. High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions.
Di Niro R; Mesin L; Zheng NY; Stamnaes J; Morrissey M; Lee JH; Huang M; Iversen R; du Pré MF; Qiao SW; Lundin KE; Wilson PC; Sollid LM
Nat Med; 2012 Feb; 18(3):441-5. PubMed ID: 22366952
[TBL] [Abstract][Full Text] [Related]
6. Igs as Substrates for Transglutaminase 2: Implications for Autoantibody Production in Celiac Disease.
Iversen R; Fleur du Pré M; Di Niro R; Sollid LM
J Immunol; 2015 Dec; 195(11):5159-68. PubMed ID: 26503953
[TBL] [Abstract][Full Text] [Related]
7. Secretion of celiac disease autoantibodies after in vitro gliadin challenge is dependent on small-bowel mucosal transglutaminase 2-specific IgA deposits.
Stenman SM; Lindfors K; Korponay-Szabo IR; Lohi O; Saavalainen P; Partanen J; Haimila K; Wieser H; Mäki M; Kaukinen K
BMC Immunol; 2008 Feb; 9():6. PubMed ID: 18312620
[TBL] [Abstract][Full Text] [Related]
8. T-cell and B-cell immunity in celiac disease.
du Pré MF; Sollid LM
Best Pract Res Clin Gastroenterol; 2015 Jun; 29(3):413-23. PubMed ID: 26060106
[TBL] [Abstract][Full Text] [Related]
9. Epitope-dependent Functional Effects of Celiac Disease Autoantibodies on Transglutaminase 2.
Hnida K; Stamnaes J; du Pré MF; Mysling S; Jørgensen TJ; Sollid LM; Iversen R
J Biol Chem; 2016 Dec; 291(49):25542-25552. PubMed ID: 27784785
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Detection of Isopeptides between Human Tissue Transglutaminase and Gluten Peptides.
Lexhaller B; Ludwig C; Scherf KA
Nutrients; 2019 Sep; 11(10):. PubMed ID: 31547042
[TBL] [Abstract][Full Text] [Related]
11. Interplay between Type 2 Transglutaminase (TG2), Gliadin Peptide 31-43 and Anti-TG2 Antibodies in Celiac Disease.
Martucciello S; Sposito S; Esposito C; Paolella G; Caputo I
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456177
[TBL] [Abstract][Full Text] [Related]
12. Constitutive Differential Features of Type 2 Transglutaminase in Cells Derived from Celiac Patients and from Healthy Subjects.
Paolella G; Nanayakkara M; Sposito S; Lepretti M; Auricchio S; Esposito C; Barone MV; Martucciello S; Caputo I
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059410
[TBL] [Abstract][Full Text] [Related]
13. Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects.
Paolella G; Lepretti M; Barone MV; Nanayakkara M; Di Zenzo M; Sblattero D; Auricchio S; Esposito C; Caputo I
Amino Acids; 2017 Mar; 49(3):541-550. PubMed ID: 27613408
[TBL] [Abstract][Full Text] [Related]
14. Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.
Büchold C; Hils M; Gerlach U; Weber J; Pelzer C; Heil A; Aeschlimann D; Pasternack R
Cells; 2022 May; 11(10):. PubMed ID: 35626704
[TBL] [Abstract][Full Text] [Related]
15. Towards Celiac-safe foods: Decreasing the affinity of transglutaminase 2 for gliadin by addition of ascorbyl palmitate and ZnCl
Engstrom N; Saenz-Méndez P; Scheers J; Scheers N
Sci Rep; 2017 Mar; 7(1):77. PubMed ID: 28250436
[TBL] [Abstract][Full Text] [Related]
16. The preferred substrates for transglutaminase 2 in a complex wheat gluten digest are Peptide fragments harboring celiac disease T-cell epitopes.
Dørum S; Arntzen MØ; Qiao SW; Holm A; Koehler CJ; Thiede B; Sollid LM; Fleckenstein B
PLoS One; 2010 Nov; 5(11):e14056. PubMed ID: 21124911
[TBL] [Abstract][Full Text] [Related]
17. Type 2 Transglutaminase in Coeliac Disease: A Key Player in Pathogenesis, Diagnosis and Therapy.
Paolella G; Sposito S; Romanelli AM; Caputo I
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886862
[TBL] [Abstract][Full Text] [Related]
18. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study.
Rauhavirta T; Oittinen M; Kivistö R; Männistö PT; Garcia-Horsman JA; Wang Z; Griffin M; Mäki M; Kaukinen K; Lindfors K
J Clin Immunol; 2013 Jan; 33(1):134-42. PubMed ID: 22878839
[TBL] [Abstract][Full Text] [Related]
19. Management of celiac disease in daily clinical practice.
Elli L; Ferretti F; Orlando S; Vecchi M; Monguzzi E; Roncoroni L; Schuppan D
Eur J Intern Med; 2019 Mar; 61():15-24. PubMed ID: 30528262
[TBL] [Abstract][Full Text] [Related]
20. Enhanced B-Cell Receptor Recognition of the Autoantigen Transglutaminase 2 by Efficient Catalytic Self-Multimerization.
Stamnaes J; Iversen R; du Pré MF; Chen X; Sollid LM
PLoS One; 2015; 10(8):e0134922. PubMed ID: 26244572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
